You are here:Home-Research Areas-Cancer-Pancreatic Cancer

Request The Product List ofPancreatic Cancer Pancreatic Cancer

Cat. No. Product Name CAS No. Information



Saridegib (Patidegib, IPI-926) is a potent and orally active Hedgehog (Hh) pathway antagonist with IC50 of 7 nM; binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO; demonstrates improved pharmaceutical properties and potency and a favorable pharmacokinetic profile relative to cyclopamine and IPI-269609; completely suppresses tumor growth in a Hh-dependent medulloblastoma allograft model.

Pancreatic Cancer

Phase 2 Clinical




PF-4136309 (INCB8761) is a potent, selective, competitive, reversible full CCR2 antagonist with IC50 of 2-5 nM; depletes inflammatory monocytes and macrophages from the primary tumor and premetastatic liver resulting in enhanced antitumor immunity, decreased tumor growth, and reduced metastasis.

Pancreatic Cancer

Phase 2 Clinical


AZD 5069


AZD 5069 (AZD5069) is a potent, selective, slowly reversible and orally bioavailable CXCR2 antagonist that inhibits CXCL8 binding to CXCR2 with pIC50 of 9.1; weakly inhibits CXCL8 binding to CXCR1 with pIC50<7, and no affinity for CCR2 and CCR5; inhibits neutrophil chemotaxis with pA2 of 9.6, and adhesion molecule expression of 6.9, in response to CXCL1; demonstrates potential activity in acute LPS-induced lung inflammation models.

Pancreatic Cancer

Phase 2 Clinical




SLC-0111 is a sulfonamide carbonic anhydrase (CA, EC inhibitor with IC50 of 45 nM and 4.5 nM for tumor-associated enzymes hCA IX and hCA XII; showed selective CA IX/XII inhibitory profiles, displays >20-fold and >100-fold selectivity over hCA II and hCA I, respectively; reduces tumor cell growth and increases apoptotic cell death in prostate cancer cells.

Pancreatic Cancer

Phase 1


GNE-140 racemate


The racemate of GNE-140, a novel potent, selective lactate dehydrogenase (LDH) inhibitor with IC50 of 3, 5, and 5 nM for LDHA, LDHB, and LDHC, respectively; displays no inhibition on malate MDH-1, MDH-2 (IC50>10 uM for both enzymes), and no appreciable inhibition against a panel of 301 kinases (<50% inhibition at 1 uM); perturbs glycolysis and inhibits proliferation in MIA PaCa-2 cells (IC50=0.43 uM), decreases glucose uptake (IC50=0.47 uM); pancreatic cell lines that utilize oxidative OXPHOS rather than glycolysis are inherently resistant to GNE-140, which can be resensitized to GNE-140 with the OXPHOS inhibitor phenformin.

Pancreatic Cancer

Phase 1 Clinical


Bleomycin sulfate


An anticancer agent that acts by induction of DNA strand breaks; also inhibits incorporation of thymidine into DNA strands; a hybrid peptide-polyketide natural product.

Pancreatic Cancer

Phase 3 Clinical




GSK-2256098 (GTPL-7939) is a potent, selective, reversible and ATP-competitive inhibitor of FAK kinase with Ki of 0.4 nM; dispalys high selectivity over a panel of 261 kinases, including the nearest FAK family member, Pyk2 (>1,000-fold); inhibits FAK activity through targeting the phosphorylation site of FAK Y397; decreases levels of phosphorylated Akt and ERK, cell viability, anchorage-independent growth, and motility in L3.6P1 cells; causes lower microvessel density, less cellular proliferation, and higher apoptosis rates in the Ishikawa model.

Pancreatic Cancer

Phase 2 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us